Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders

 Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders

Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders

Shots:

  • Takeda and Frazier enter into collaboration to launch Phathom Pharmaceuticals to develop & commercialize therapies for gastrointestinal diseases and disorders
  • Phathom to get rights to develop & exclusively commercialize Takeda’s Vonoprazan in the US, EU & Canada plus $90M funds & $50M as debt facility from Frazier & Silicon Valley Bank respectively. Takeda to get upfront as cash & equity, milestones, royalties on sales and will retain its right for Asia
  • Takeda’s vonoprazan is an orally active potassium-competitive acid blocker (P-CAB), blocking the potassium binding site of ATPase indicated for acid-related disorders like GERD, co-promoted by Takeda & Otsuka under 2015 deal

Click here to read full press release/ article | Ref: BusinessWire | Image: Biotechin.Asia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post